x

Posted 07 December, 2023

Hepion Pharmaceuticals, Inc. appointed John Cavan as new CEO

Nasdaq:HEPA appointed new Chief Executive Officer John Cavan in a 8-K filed on 07 December, 2023.


  On December 4, 2023, the Board of Directors appointed John Cavan, the Company's Chief Financial Officer, as interim Chief Executive Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Hepion Pharmaceuticals, Inc.
Health Care/Life Sciences • Biotechnology
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Market Cap
$12.3M
View Company Details
Hepion Pharmaceuticals, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. 


On December 4, 2023, Dr. Robert Foster, the Company's CEO, resigned from the Company as CEO for personal reasons, effective immediately. In connection therewith, on December 4, 2023, Dr. Foster resigned from the Board of Directors of the Company.


On December 4, 2023, the Board of Directors appointed John Cavan, the Company's Chief Financial Officer, as interim Chief Executive Officer.


On December 4, 2023, Dr. Peter Wijngaard resigned from the Board of Directors of the Company. Dr. Wijngaard was a member of the Company's Audit Committee.